2018 has flown by, and 2019 is just around the corner! As the New Year approaches, it’s good to look back at just how much has been accomplished in the field of medicine, and wonder what the future holds. As is our tradition at this time of year, we are pleased to present HemaCare’s 10 most popular blogs of the year, and the advances in healthcare that they represent. Enjoy the countdown!
Combining checkpoint inhibitor cancer immunotherapy with CAR-T cell approaches that target interleukin (IL)-13R2a has proven to be more effective for treating glioblastoma than using either treatment alone.
“Bystander” T cells have recently been shown to counteract the inflammatory actions of antigen-specific cytotoxic T cells. Their presence can help limit tissue damage in autoimmune disease.
This blog highlights how the availability of disease state cells and tissue samples helps scientists characterize the cellular and molecular features of a disease and its progression. Identifying biomarkers linked to early disease detection can improve disease management and prognosis.
Cryopreserving cells can be used to preserve therapeutic efficacy during shipping and storage, as well as providing on-demand treatment availability and consistency.
Glioblastoma is a form of cancer which is very difficult to treat since tumors have mixed cell populations. Recent immunotherapy strategies are having promising results.
Dendritic cell-based anticancer vaccines have the potential to significantly increase cancer survival rates and improve the quality of life and function with fewer adverse effects.
This blog features a new HemaCare publication in the popular online regenerative medicine journal RegMedNet. The article covers how to optimize various aspects of apheresis and cell collection in order to improve cell and gene therapy starting material quality. Donor networks, process development, apheresis devices, and quality management systems are discussed.
- HemaCare to supply pre-screened PBMCs to facilitate engraftment of human cells for Charles River’s new NCG mouse humanization kit
HemaCare and Charles River have partnered to create a new mouse humanization kit using PBMCs preselected for rapid engraftment in the NCG mouse model.
HemaCare leukopaks are being used in a study focused on using an engineered fusion protein to enhance T cell activation, signaling, and proliferation. This fusion protein is now being evaluated in a multi-center Phase-1 clinical trial in human cancer patients with solid tumors.
And finally, our #1 blog post from 2018... drum roll please:
Our most popular blog post for 2018 focused on one of the most important aspects of cell and gene therapy; optimizing starting material quality and consistency. We present important tips on apheresis training, cell collection, and preserving cell viability and function.
We hope you enjoy checking out these blogs, and that the New Year brings many more fascinating medical advances. HemaCare wishes all of you a healthy and happy 2019!